GERN 241115 4.00P (GERN241115P4000) Stock Options, News & Quotes

0.25
-0.02-7.41%

15min DelayClose Oct 25 16:00 ET

0.30High0.25Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Tonyco

5 hours ago

$Geron (GERN.US)$ Really wants to just chill at 4

generous Llama_6844

Oct 17 08:18

Time to dips from the support line , target 4.7 , 10% -15% ROI

$Geron (GERN.US)$ $Geron (GERN.US)$

Trung Luong

Sep 2 13:48

$Geron (GERN.US)$ For those who is new to this company, here is a summary: JNJ paid 250M a year to co develop the drug 5 years ago. They didn’t want to continue the second year which the price was low 5 n drop to lowest of 1.30 in the next 2 years. Gern continue to drug development with the 250M from JNJ to get it FDA approval few months ago to which they raised 450M for reserve cash. The stock went up to hitting 52 weeks high of 5.34 in the next month or two of FDA approval. You now are caught...

Trung Luong

Sep 2 07:13

$Geron (GERN.US)$ this is the month I have been waiting for since Feb as per news on 1) partnership or 2) buy out. Go alone will have its risk n reward which they secure 420M to do it to last early 2026. If its #1 then expect stock 7-8 range, #2- Like to see 10-15 range.Lets beat my #1 niotech buyout imgn return with this prediction.

Trytosaveabit

Jul 26 06:42

Hmm

$Geron (GERN.US)$ Geron Announces Updated Nccn Guidelines® Recommending Rytelo™ (Imetelstat) for the Treatment of Symptomatic Anemia in Patients With Lower-Risk Mds